Patents Assigned to Myokardia, Inc.
-
Patent number: 11873289Abstract: The present invention provides processes for preparation of substituted pyrazole compounds of formula II, that can be used as intermediates for preparation of substituted piperidine urea compounds useful for the treatment of dilated cardiomyopathy (DCM). R2 is independently selected from F, C1-C4 alkyl, C1-C4 haloalkyl, R3 is independently selected from H, F, C1-C4 alkyl, C1-C4 haloalkyl, R4 is C1-C4 alkyl, R6 is H or a protecting group and R7 is selected from H, CI or trialkylsilyl.Type: GrantFiled: February 1, 2019Date of Patent: January 16, 2024Assignee: MyoKardia, Inc.Inventors: Sunil Sharma, Dinesh Jangid, Priyanka Dhaka, Siddharth Madhwal, Bharat Kumar, Kapil Kumar, Rajdeep Anand, Anurag Jain
-
Publication number: 20220265629Abstract: Provided herein are methods, use, and compositions for treating systolic dysfunction such as heart failure with reduced ejection fraction.Type: ApplicationFiled: May 18, 2020Publication date: August 25, 2022Applicant: MyoKardia, Inc.Inventors: Jean-Francois Tamby, Chun Yang, Timothy Carlson
-
Patent number: 11123337Abstract: The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.Type: GrantFiled: July 21, 2020Date of Patent: September 21, 2021Assignee: MyoKardia, Inc.Inventors: Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
-
Patent number: 11034693Abstract: The present disclosure provides novel 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones of formula (I): The compounds of formula (I) are useful for the treatment of hypertrophic cardiomyopathy (HCM), conditions associated with left ventricular hypertrophy, conditions associated with diastolic dysfunction, and/or symptoms associated thereof. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.Type: GrantFiled: October 28, 2019Date of Patent: June 15, 2021Assignee: MyoKardia, Inc.Inventors: Mark Grillo, Brian Kane, Johan Oslob, Min Zhong, Fabienne Thompson
-
Patent number: 10758525Abstract: The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.Type: GrantFiled: October 2, 2018Date of Patent: September 1, 2020Assignee: MyoKardia, Inc.Inventors: Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
-
Patent number: 9925177Abstract: The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.Type: GrantFiled: January 21, 2016Date of Patent: March 27, 2018Assignee: MyoKardia, Inc.Inventors: Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
-
Patent number: 9663516Abstract: The present invention provides novel bicyclic pyrimidinedione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.Type: GrantFiled: December 17, 2015Date of Patent: May 30, 2017Assignee: MYOKARDIA, INC.Inventors: Johan Oslob, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Mark Grillo, Brian Kane, Robert McDowell, Yonghong Song, Min Zhong
-
Patent number: 9585883Abstract: Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.Type: GrantFiled: October 14, 2015Date of Patent: March 7, 2017Assignee: MYOKARDIA, INC.Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran
-
Patent number: 9199945Abstract: The present invention provides novel cycloalkyl-substituted pyrimidine dione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.Type: GrantFiled: June 19, 2014Date of Patent: December 1, 2015Assignee: Myokardia, Inc.Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran, Pu-Ping Lu
-
Patent number: 9181200Abstract: Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.Type: GrantFiled: June 19, 2014Date of Patent: November 10, 2015Assignee: Myokardia, Inc.Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran
-
Patent number: RE50050Abstract: Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.Type: GrantFiled: March 19, 2022Date of Patent: July 23, 2024Assignee: MyoKardia, Inc.Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran